Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca shares tumbled on Thursday after the company said its nerve disease ...

The drugmakers said the drug didn’t meet its primary objective in a Phase 3 trial when treating a rare type of heart disease.

Biogen (BIIB) stock dips as the company updates Phase 2 trial data for diranersen, an Alzheimer’s drug developed with Ionis ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...

Ionis Pharmaceuticals (IONS) stock falls as Roche (RHHBY) discontinues two experimental therapies for Huntington’s disease ...

Patients who have a particular genetic disease whose symptoms include progressively worsening muscle control were able to walk faster following treatment with an experimental Ionis Pharmaceuticals ...

AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio’s approved ATTR-CM treatment.

TheFly reported on June 25 that H.C. Wainwright increased its price target on IONS to $130 from $125 while maintaining a Buy ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals reported on Tuesday that a drug approved for a rare disease ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...